Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Olfactory Bulb | 18 | 2021 | 48 | 5.850 |
Why?
|
| Endocannabinoids | 8 | 2024 | 39 | 3.290 |
Why?
|
| Smell | 8 | 2021 | 36 | 2.470 |
Why?
|
| Neurons | 17 | 2021 | 1175 | 2.250 |
Why?
|
| Olfaction Disorders | 4 | 2024 | 9 | 2.100 |
Why?
|
| Olfactory Pathways | 7 | 2013 | 14 | 1.610 |
Why?
|
| Cannabinoids | 3 | 2021 | 56 | 1.470 |
Why?
|
| Synaptic Transmission | 10 | 2018 | 146 | 1.420 |
Why?
|
| Oils, Volatile | 2 | 2020 | 13 | 1.340 |
Why?
|
| Neuronal Plasticity | 5 | 2021 | 103 | 1.270 |
Why?
|
| Signal Transduction | 6 | 2020 | 1908 | 1.170 |
Why?
|
| Analgesics | 2 | 2018 | 54 | 1.110 |
Why?
|
| Interneurons | 5 | 2019 | 56 | 1.060 |
Why?
|
| Brain | 5 | 2018 | 1346 | 1.040 |
Why?
|
| Receptors, Metabotropic Glutamate | 6 | 2009 | 28 | 1.010 |
Why?
|
| Receptors, GABA-A | 4 | 2018 | 64 | 0.990 |
Why?
|
| Receptor, Cannabinoid, CB1 | 3 | 2021 | 40 | 0.970 |
Why?
|
| Receptors, Cannabinoid | 2 | 2015 | 26 | 0.960 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2019 | 79 | 0.940 |
Why?
|
| Neurodegenerative Diseases | 2 | 2021 | 131 | 0.860 |
Why?
|
| Animals | 36 | 2024 | 15081 | 0.860 |
Why?
|
| Patch-Clamp Techniques | 12 | 2019 | 223 | 0.830 |
Why?
|
| Ageusia | 1 | 2021 | 2 | 0.810 |
Why?
|
| Epigenesis, Genetic | 3 | 2023 | 219 | 0.780 |
Why?
|
| Visual Pathways | 1 | 2021 | 38 | 0.770 |
Why?
|
| Brachial Artery | 1 | 2021 | 28 | 0.770 |
Why?
|
| Olfactory Receptor Neurons | 3 | 2013 | 28 | 0.770 |
Why?
|
| Visual Perception | 1 | 2021 | 67 | 0.770 |
Why?
|
| Manduca | 5 | 2004 | 9 | 0.750 |
Why?
|
| Energy Intake | 1 | 2021 | 170 | 0.720 |
Why?
|
| Body Composition | 1 | 2021 | 162 | 0.710 |
Why?
|
| Terpenes | 1 | 2020 | 28 | 0.710 |
Why?
|
| Cannabis | 2 | 2018 | 79 | 0.680 |
Why?
|
| Pheromones | 4 | 2000 | 18 | 0.680 |
Why?
|
| Mice, Inbred C57BL | 10 | 2019 | 1609 | 0.640 |
Why?
|
| Neurotransmitter Agents | 1 | 2018 | 63 | 0.630 |
Why?
|
| Marijuana Abuse | 2 | 2018 | 91 | 0.630 |
Why?
|
| Anti-Anxiety Agents | 1 | 2018 | 15 | 0.630 |
Why?
|
| Exercise | 2 | 2021 | 613 | 0.630 |
Why?
|
| Sodium Channels | 1 | 2018 | 67 | 0.610 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 71 | 0.600 |
Why?
|
| Synapses | 6 | 2012 | 180 | 0.570 |
Why?
|
| Sodium Channel Blockers | 2 | 2017 | 17 | 0.560 |
Why?
|
| Humans | 26 | 2024 | 37093 | 0.550 |
Why?
|
| Nerve Net | 3 | 2013 | 76 | 0.550 |
Why?
|
| Anticonvulsants | 2 | 2018 | 34 | 0.540 |
Why?
|
| Eugenol | 1 | 2015 | 6 | 0.520 |
Why?
|
| Anesthetics | 1 | 2015 | 11 | 0.510 |
Why?
|
| Pain | 1 | 2018 | 251 | 0.510 |
Why?
|
| Bufanolides | 1 | 2014 | 2 | 0.510 |
Why?
|
| Action Potentials | 8 | 2017 | 231 | 0.460 |
Why?
|
| Prosencephalon | 1 | 2013 | 25 | 0.460 |
Why?
|
| Resistance Training | 2 | 2023 | 18 | 0.460 |
Why?
|
| Neuroprotective Agents | 2 | 2018 | 245 | 0.450 |
Why?
|
| Blood Pressure | 3 | 2021 | 646 | 0.430 |
Why?
|
| Amygdala | 4 | 2000 | 114 | 0.420 |
Why?
|
| Neural Inhibition | 4 | 2008 | 48 | 0.420 |
Why?
|
| Male | 25 | 2024 | 20025 | 0.400 |
Why?
|
| Ginsenosides | 1 | 2011 | 4 | 0.400 |
Why?
|
| Panax | 1 | 2011 | 7 | 0.400 |
Why?
|
| Mice | 11 | 2019 | 5913 | 0.400 |
Why?
|
| GABA Modulators | 1 | 2010 | 1 | 0.390 |
Why?
|
| Anxiety | 1 | 2018 | 754 | 0.380 |
Why?
|
| Glutamic Acid | 2 | 2011 | 128 | 0.380 |
Why?
|
| Retina | 2 | 2024 | 280 | 0.360 |
Why?
|
| Membrane Potentials | 7 | 2014 | 223 | 0.350 |
Why?
|
| Olfactory Nerve | 4 | 2009 | 7 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2018 | 1039 | 0.330 |
Why?
|
| Electric Stimulation | 6 | 2013 | 184 | 0.330 |
Why?
|
| Sense Organs | 2 | 1998 | 11 | 0.320 |
Why?
|
| Motor Activity | 1 | 2011 | 418 | 0.320 |
Why?
|
| Methoxyhydroxyphenylglycol | 2 | 2007 | 15 | 0.320 |
Why?
|
| Neural Pathways | 2 | 2006 | 124 | 0.320 |
Why?
|
| Piperidines | 3 | 2018 | 77 | 0.290 |
Why?
|
| Excitatory Postsynaptic Potentials | 7 | 2011 | 79 | 0.290 |
Why?
|
| Biotin | 2 | 2017 | 24 | 0.290 |
Why?
|
| Sex Attractants | 2 | 2008 | 4 | 0.270 |
Why?
|
| Optics and Photonics | 1 | 2005 | 28 | 0.270 |
Why?
|
| Organ Culture Techniques | 5 | 2011 | 103 | 0.260 |
Why?
|
| Excitatory Amino Acid Antagonists | 4 | 2012 | 99 | 0.260 |
Why?
|
| Respiratory Muscles | 2 | 2023 | 10 | 0.260 |
Why?
|
| Mice, Knockout | 3 | 2019 | 933 | 0.250 |
Why?
|
| Cricetulus | 2 | 2015 | 80 | 0.250 |
Why?
|
| Electrophysiology | 5 | 2007 | 136 | 0.250 |
Why?
|
| CHO Cells | 2 | 2015 | 124 | 0.250 |
Why?
|
| Cricetinae | 2 | 2015 | 238 | 0.250 |
Why?
|
| Circadian Rhythm | 2 | 2024 | 225 | 0.240 |
Why?
|
| Female | 17 | 2024 | 20969 | 0.240 |
Why?
|
| Natural Language Processing | 1 | 2024 | 12 | 0.240 |
Why?
|
| Exercise Tolerance | 1 | 2023 | 15 | 0.230 |
Why?
|
| Insulin-Secreting Cells | 1 | 2023 | 28 | 0.220 |
Why?
|
| Dementia | 1 | 2023 | 131 | 0.210 |
Why?
|
| Rats | 9 | 2013 | 3483 | 0.210 |
Why?
|
| Evoked Potentials | 3 | 2001 | 87 | 0.210 |
Why?
|
| Breathing Exercises | 1 | 2021 | 1 | 0.200 |
Why?
|
| Inhalation | 1 | 2021 | 8 | 0.200 |
Why?
|
| Taste Disorders | 1 | 2020 | 2 | 0.190 |
Why?
|
| Somatosensory Disorders | 1 | 2020 | 2 | 0.190 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 75 | 0.190 |
Why?
|
| Neurons, Afferent | 2 | 2006 | 43 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2013 | 1618 | 0.180 |
Why?
|
| Olfactory Mucosa | 1 | 2020 | 18 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 97 | 0.170 |
Why?
|
| Serotonin | 1 | 2000 | 123 | 0.170 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 237 | 0.170 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 61 | 0.170 |
Why?
|
| Adenosine | 1 | 1999 | 59 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 68 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 76 | 0.160 |
Why?
|
| Nitric Oxide | 1 | 2021 | 316 | 0.160 |
Why?
|
| Skin | 1 | 2020 | 174 | 0.160 |
Why?
|
| Indans | 1 | 2018 | 13 | 0.160 |
Why?
|
| Heart Rate | 1 | 2019 | 253 | 0.160 |
Why?
|
| Quinine | 1 | 2017 | 10 | 0.160 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 15 | 0.150 |
Why?
|
| Benzamides | 1 | 2018 | 78 | 0.150 |
Why?
|
| Autistic Disorder | 1 | 2017 | 37 | 0.150 |
Why?
|
| Caspase 3 | 1 | 2018 | 207 | 0.150 |
Why?
|
| Hippocampus | 2 | 2013 | 561 | 0.140 |
Why?
|
| Aging | 1 | 2021 | 664 | 0.140 |
Why?
|
| Ethanol | 1 | 2018 | 192 | 0.140 |
Why?
|
| Aged | 6 | 2024 | 6741 | 0.140 |
Why?
|
| Gene Expression | 1 | 2018 | 674 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2021 | 938 | 0.130 |
Why?
|
| GABA Antagonists | 3 | 2006 | 29 | 0.130 |
Why?
|
| Amphibian Venoms | 1 | 2014 | 1 | 0.130 |
Why?
|
| Ouabain | 1 | 2014 | 15 | 0.130 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2014 | 28 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 400 | 0.120 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 37 | 0.120 |
Why?
|
| Ion Channel Gating | 1 | 2014 | 83 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 905 | 0.120 |
Why?
|
| Hypertension | 1 | 2021 | 796 | 0.120 |
Why?
|
| Time Factors | 5 | 2021 | 1742 | 0.120 |
Why?
|
| Scopolamine | 1 | 2013 | 4 | 0.120 |
Why?
|
| Muscarinic Antagonists | 1 | 2013 | 12 | 0.120 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 10 | 0.120 |
Why?
|
| Adult | 4 | 2024 | 11712 | 0.120 |
Why?
|
| Central Nervous System | 1 | 2014 | 135 | 0.120 |
Why?
|
| Muscle Strength | 2 | 2023 | 29 | 0.110 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 22 | 0.110 |
Why?
|
| Middle Aged | 6 | 2024 | 10129 | 0.110 |
Why?
|
| Neurogenesis | 1 | 2013 | 58 | 0.110 |
Why?
|
| Suprachiasmatic Nucleus | 2 | 2024 | 43 | 0.110 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2012 | 5 | 0.110 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2012 | 15 | 0.110 |
Why?
|
| Arachidonic Acids | 1 | 2012 | 24 | 0.110 |
Why?
|
| Naphthalenes | 1 | 2012 | 38 | 0.100 |
Why?
|
| Benzoxazines | 1 | 2012 | 46 | 0.100 |
Why?
|
| Morpholines | 1 | 2012 | 69 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 111 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2023 | 286 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2012 | 85 | 0.100 |
Why?
|
| Rats, Long-Evans | 3 | 2000 | 89 | 0.100 |
Why?
|
| Allosteric Regulation | 1 | 2010 | 22 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 360 | 0.100 |
Why?
|
| Astrocytes | 1 | 2013 | 255 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 730 | 0.100 |
Why?
|
| Thalamus | 2 | 2000 | 30 | 0.090 |
Why?
|
| Cell Count | 2 | 2013 | 135 | 0.090 |
Why?
|
| Dendrites | 1 | 2009 | 55 | 0.090 |
Why?
|
| Alkadienes | 2 | 2008 | 6 | 0.080 |
Why?
|
| Cerebral Cortex | 2 | 2000 | 290 | 0.080 |
Why?
|
| Protein Binding | 1 | 2010 | 972 | 0.080 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2006 | 48 | 0.070 |
Why?
|
| Photolysis | 1 | 2005 | 25 | 0.070 |
Why?
|
| United States | 1 | 2015 | 4223 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 623 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 36 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2721 | 0.060 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 35 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 98 | 0.060 |
Why?
|
| Aldehydes | 1 | 2004 | 69 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 218 | 0.060 |
Why?
|
| Respiratory Therapy | 1 | 2023 | 3 | 0.060 |
Why?
|
| DNA Primers | 1 | 2004 | 286 | 0.060 |
Why?
|
| DNA | 1 | 2007 | 574 | 0.060 |
Why?
|
| Muscles | 1 | 2023 | 82 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2023 | 73 | 0.060 |
Why?
|
| Hand Strength | 1 | 2023 | 34 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2023 | 77 | 0.060 |
Why?
|
| Base Sequence | 1 | 2004 | 997 | 0.050 |
Why?
|
| Young Adult | 2 | 2024 | 4268 | 0.050 |
Why?
|
| Tetrodotoxin | 2 | 2017 | 22 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2001 | 14 | 0.050 |
Why?
|
| Colorado | 1 | 2021 | 15 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2001 | 110 | 0.050 |
Why?
|
| Glucose | 1 | 2023 | 230 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 885 | 0.050 |
Why?
|
| Receptors, GABA | 1 | 2000 | 25 | 0.050 |
Why?
|
| Taste | 1 | 2020 | 41 | 0.050 |
Why?
|
| Nervous System | 1 | 2000 | 29 | 0.050 |
Why?
|
| Nerve Fibers | 1 | 2000 | 34 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2023 | 308 | 0.050 |
Why?
|
| Xanthines | 1 | 1999 | 1 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1999 | 7 | 0.040 |
Why?
|
| Bicuculline | 1 | 1999 | 18 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2023 | 325 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2000 | 137 | 0.040 |
Why?
|
| Organophosphorus Compounds | 1 | 1999 | 37 | 0.040 |
Why?
|
| Oscillometry | 1 | 1998 | 7 | 0.040 |
Why?
|
| Rodentia | 1 | 2018 | 43 | 0.040 |
Why?
|
| Chemoreceptor Cells | 1 | 1998 | 20 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 739 | 0.040 |
Why?
|
| Central Nervous System Depressants | 1 | 2018 | 37 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 20 | 0.040 |
Why?
|
| Potassium Channel Blockers | 1 | 2017 | 33 | 0.040 |
Why?
|
| Pluripotent Stem Cells | 1 | 2017 | 32 | 0.040 |
Why?
|
| Substantia Nigra | 1 | 2017 | 44 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 177 | 0.040 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2017 | 78 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2018 | 129 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1518 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1369 | 0.040 |
Why?
|
| Calcium | 1 | 2000 | 480 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2017 | 118 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 1998 | 230 | 0.040 |
Why?
|
| Mental Processes | 1 | 1996 | 15 | 0.030 |
Why?
|
| Invertebrates | 1 | 1996 | 15 | 0.030 |
Why?
|
| Vertebrates | 1 | 1996 | 29 | 0.030 |
Why?
|
| Brain Mapping | 1 | 1996 | 112 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 1354 | 0.030 |
Why?
|
| Receptors, GABA-B | 2 | 2006 | 11 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 33 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2231 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2008 | 22 | 0.020 |
Why?
|
| Lepidoptera | 1 | 2008 | 9 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 181 | 0.020 |
Why?
|
| Tacrine | 1 | 2006 | 1 | 0.020 |
Why?
|
| Xanthenes | 1 | 2006 | 11 | 0.020 |
Why?
|
| Benzoates | 1 | 2006 | 16 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2006 | 47 | 0.020 |
Why?
|
| Glycine | 1 | 2006 | 47 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2006 | 73 | 0.020 |
Why?
|
| Cell Shape | 1 | 2005 | 35 | 0.020 |
Why?
|
| Amino Acids | 1 | 2006 | 145 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 208 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 617 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 34 | 0.010 |
Why?
|
| Phosphinic Acids | 1 | 2000 | 3 | 0.010 |
Why?
|
| Propanolamines | 1 | 2000 | 12 | 0.010 |
Why?
|
| Afferent Pathways | 1 | 2000 | 37 | 0.010 |
Why?
|
| Receptors, Glycine | 1 | 2000 | 7 | 0.010 |
Why?
|
| N-Methylaspartate | 1 | 2000 | 57 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2000 | 145 | 0.010 |
Why?
|